论文部分内容阅读
Background/aims: Advanced glycation end products (AGEs)-are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceraldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. The aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease. Methods: Sera were obtained from 31 patients with active VKH. 20 of these 31 patients were treated with systemic corticosteroids. As controls, 33 healthy volunteers were also examined. The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody. Results: The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23) U/ml, which was significantly lower than that of the healthy control subjects (8.32 (2.94), p < 0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U/ml after the patients were treated with systemic corticosteroids (p < 0.001). Conclusions: These results suggest that AGE-2 may be involved in the onset of VKH disease.
Background / aims: Advanced glycation end products (AGEs) -are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceraldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease. Methods: Sera were obtained from 31 patients with active VKH. 20 of these 31 patients were treated with systemic corticosteroids. As controls, The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody. Results: The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23 ) Was U / ml, which was significantly lower than that of the healthy control subjects (8.32 (2.94), p <0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U / ml after the patients were treated with systemic cort icosteroids (p <0.001). Conclusions: These results suggest that AGE-2 may be involved in the onset of VKH disease.